A review of the treatment for refractory obsessive-compulsive disorder: From medicine to deep brain stimulation

CNS Spectrums

Volumn 9, Issue 11, 2004, Pages 833-847

  Husted, David S ^a   Shapira, Nathan A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; LAMOTRIGINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PAROXETINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN; VENLAFAXINE;

BRAIN DEPTH STIMULATION; CINGULATE GYRUS; CINGULECTOMY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; HUMAN; LEUKOTOMY; LIMBIC CORTEX; MINIMALLY INVASIVE SURGERY; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOSURGERY; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; STIMULUS RESPONSE; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION;

EID: 10044226327     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285290000225X     Document Type: Review

References (150)

1. Stein DJ, Stone MH. Essential Papers on Obsessive-Campulsive Disorders. New York, NY: New York University Press; 1997.
2. Karno M, Goldin JM, Sorenson SB, et al. The epidemiology of obsessive compulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45:1094-1099.
3. Bebbington PE. Epidemiology of obsessive-compulsive disorder. Br J Psychiatry. 1998;35(suppl):2-6.
4. Eichstedt JA, Arnold SL. Childhood-onset obsessive-compulsive disorder: a tic-related subtype of OCD? Clin Psychol Rev. 2001;21:137-157.
5. Geller PA, Klier CM, Neugebauer R. Anxiety disorders following miscarriage. J Clin Psychiatry. 2001;62:432-438.
6. Williams KE, Koran LM. Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum. J Clin Psychiatry. 1997;58:330-334.
7. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry. 1998;155:264-271.
8. Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1999;56:121-127.
9. Hollander E, Greenwald S, Neville D, Johnson J, Hornig CD, Weissman MM. Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiologic sample. Depress Anxiety. 1997;4:111-119.
10. Hollander E. Obsessive-Compulsive Related Disorders. Washington, DC: American Psychiatric Press; 1993.
11. Dupont RL, Rice DP, Shiraki S, et al. Economic costs of obsessive-compulsive disorder. Med Interface. 1995;8:102-109.
12. Newth S, Rachman S. The concealment of obsessions. Behav Res Ther. 2001;39:457-464.
13. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown obsessive compulsive scale. I: development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
14. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown obsessive compulsive scale. II: validity. Arch Gen Psychiatry. 1989;46:1012-1016.
15. Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children's Yale-Brown bsessive compulsive scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997;36:844-852.
16. Stein DJ, Hollander E, and Cohen L. Neuropsychiatry of obsessive-compulsive disorder. In: Hollander E, Zohar J, Marazziti D, Olivier B, eds. Current Insights in Obsessive-Compulsive Disorder. Chicester, UK: Wiley; 1994:167-182.
17. Rauch SL, Baxter LR Jr. Neuroimaging in obsessive-compulsive disorder and related disorders. In: Jenicke MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Practical Management. 3rd ed. St Louis, Mo: Mosby; 1998:289-317.
18. Rosenberg DR, Keshavan MS. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biol Psychiatry. 1998;43:623-640.
19. Hugo F, van Heerden BB, Zungu-Dirwayi N, Stein DJ. Functional brain imaging in obsessive-compulsive disorder secondary to neurological lesions. Depress Anxiety. 1999;10:129-136.
20. Zungu-Dirwayi N, Hugo F, van Heerden BB, Stein DJ. Are musical obsessions a temporal lobe phenomenon? J Neuropsychiatty Clin Neurosci. 1999;11:398-400.
21. Szeszko PR, Robinson D, Alvir JMJ, et al. Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch Gen Psychiatry. 1999;56:913-19.
22. Baxter LR, Schwartz JM, Bergman KS, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for OCD. Arch Gen Psychiatry. 1992;49:681-689.
23. Tot S, Ozge A, Comelekoglu U, et al. Association of QEEG findings with clinical characteristics of OCD: evidence of left frontotemporal dysfunction. Can J Psychiatry. 2002;47:538-545.
24. Bergqvist PB, Dong J, Blier P. Effect of atypical antipsychotic drugs on 5-HT2 receptors in the rat orbito-frontal cortex: an in vivo electrophysiological study. Psychophamacology. 1999;143:89-96.
25. Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2001;11:169-172.
26. Stern L, Zohar J, Cohen R, Sasson Y. Treatment of severe, drug resistant obsessive compulsive disorder with the 5-HT(1D) agonist sumatriptan. Eur Neuropsychopnamacol. 1998;8:325-328.
27. Mundo E, Richter MA, Sam F, Macciardi F, Kennedy JL. Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am J Psychiatry. 2000;157:1160-1161.
28. Stein DJ, van Heerden BB, Wessels CJ, et al. Single photon emission computed tomography of the brain with tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharm Biol Psychiatry. 1999;23:1079-1099.
29. El Mansari M, Bouchard C, Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Neuropsychopharmacology. 1995;13:117-127.
30. Goodman WK, McDougle CJ, Lawrence LP. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder. J Clin Psychiatry. 1990;51(suppl):36-43.
31. Swedo SE, Rapaport JL, Cheslow DL, et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry. 1989;146:246-249.
32. Leonard HL, Swedo SE. Pediatric autoimmune neuropsychiatric disorders associated with streptoccccal infection (PANDAS). Int J Neuropsychoprarmacol. 2001;4:191-198.
33. Eisen JL, Leonard HL, Swedo SE, et al. The use of antibody D8/17 to identify B cells in adults with obsessive-compulsive disorder. Psychiatry Res. 2001;104:221-225.
34. Stein DJ, Goodman WK, Rauch SL. The cognitive-affective neuroscience of obsessive-compulsive disorder. Curr Psychiatry Rep. 2000;2:341-346.
35. Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorder in childhood. Lancet. 1999;354:1153-1158.
36. Goodman WK, Ward HE, Kablinger AS, Murphy TK. Biological approaches to treatment-resistant obsessive-compulsive disorder. In: Goodman WK, Rudorfer MV, and Maser JD, eds. Obsessive-Compulsive Disorder: Contemporary Issues in Management. London, UK: Lawrence Erlbaum Associates; 2000:333-369.
37. Grados MA, Riddle MA. Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice. J Clin Child Psychol 2001;30:67-79.
38. Dougherty DD, Rauch SL, Jenike MA. Pharmacological treatments for obsessive compulsive disorder. In: Nathan PE, Gorman JM, eds. A Guide to Treatments That Work. 2nd ed. London, UK: Oxford University Press; 2002:387-410.
39. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289-295.
40. Tollefson G, Birkett M, Koran L, Genduso L. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry. 1994;55:69-78.
41. Wheadon DE, Bushnell WD, Steiner M. A fixed-dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of OCD. Paper presented at: Annual Meeting of the American College of Neuropsychopharmacology; December 7-11, 1993; Honolulu, Hawaii.
42. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison of fluvoxamine and placebo. Arch Gen Psychiatry. 1989;46:36-40.
43. Geller DA, Biederman J, Stewart SE, et al. Which SSR? A meta-analysis of pharmacotherapy in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003;160:1919-1928.
44. March JS, Frances A, Carpenter D, Kahn D. Treatment of obsessive-compulsive disorder. The Expert Consensus Panel for obsessive-compulsive disorder. J Clin Psychiatry. 1997;58(suppl):1-72.
45. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1998;37(suppl):27-45.
46. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry. 2001;62(suppl):5-9.
47. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51:302-308.
48. Albert U, Bergesio C, Pessina E, et al. Management of treatment resistant obsessive-compulsive disorder: algorithms for pharmacotherapy. Panminerva Med. 2002;44:83-91.
49. Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmocology. 2003;28:402-412
50. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794-802.
51. Hollander E, Ross NB, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo controlled study. Int J Neuropsychopharmocol. 2003;6:397-401.
52. Arias F, Soto JA, Garcia MJ, et al. Efficacy and tolerance of risperidone addition in serotonin reuptake inhibitors (SRI) treatment for refractory obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2002;12(suppl 3):S341.
53. D'Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:619-623.
54. Crocq MA, Leclercq P, Guillon MS, Bailey PE. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment. Eur Psychiatry. 2002;17:296-297.
55. Bystritsky A, Ackerman DL, Rosen RM, et al. Augmentation of SSRI response in refractory OCD using adjunct olanzapine: a placebo-controlled trial. APA Annual Meeting, New Research Abstracts; 2001: New Orleans, LA:171-172.
56. Shapira NA, Ward HE, Mandoki M, et al. Placebo-controlled trial of fluoxetine versus fluoxetine plus olanzapine in obsessive-compulsive disorder. Paper presented at: Annual Meeting of the New Clinical Drug Evaluation Unit; May 29, 2003; Boca Raton, FL.
57. Denys D, Van Megen H, Westenberg HGM. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry. 2002;63:700-702.
58. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17:115-119.
59. McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry. 1995;152:1812-1814.
60. Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics: a review of the reported cases. Prog Neuropsyschophamacol Biol Psychiatry. 2003;27:333-346.
61. de Haan L, Beuk N, Hoogenboom B, et al. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry. 2002;63:104-107.
62. Jenike MA, Baer L, Minichiello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry. 1997;154:1261-1264.
63. Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychophormocol. 1991;11:242-248.
64. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991;11:175-184.
65. Pigott TA, L'Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992;12:11-18.
66. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1993;150:647-649.
67. Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry. 1993;150:819-821.
68. Pigott TA, L'Heureux F, Rubenstein CS, et al. A double-blind, placebo-controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992;12:156-162.
69. Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive compulsive: double-blind placebo controlled trial. Eur Neuropsychomacol. 2000;10:165-169.
70. Koran LM, Mueller K, Maloney A. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder? J Clin Psychopharmacol. 1996;16:253-254.
71. Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol. 1996;11:37-44.
72. Jenike MA. Drug treatment of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive Compulsive Disorders: Theory and Management. 2nd ed. Chicago, IL: Year Book Medical; 1990:249-282.
73. Pigott TA, L'Heureux FL, Rubenstein CS. A controlled trial of clonazepam augmentation in OCD patients treated with clomipramine or fluoxetine. New Research Abstract. 144, 145th Annual Meeting of the American Psychiatric Association, Washington, DC, 1992;82.
74. Hollander E, DeCaria CM, Schneier FR, et al. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry. 1990;51:119-123.
75. Hollander E, Friedberg J, Wasserman S, et al. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2003;64:546-550.
76. Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry. 2002;63:1004-1009.
77. Denys D, Van Der Wee N, Van Megen HJ, Westenberg HG. A double-blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003;23:568-575.
78. Deltito JA. Valproate pretreatment for the difficult-to-treat patient with OCD [letter]. J Clin Psychiatry. 1994;55:500.
79. Joffe RT, Swinson RP. Carbamazepine in obsessive-compulsive disorder. Biol Psychiatry. 1987;45:122-124.
80. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder [letter]. J Clin Psychiatry. 1998;59:480-481.
81. Sporn J, Smith M, Jersino JM, et al. A double-blind, placebo-controlled trial of gabapentin augmentation of fluoxetine for treatment of obsessive-compulsive disorder (OCD) Poster presented at: New Clinical Drug Evaluation Unit Program May 28-31, 2001; Phoenix, Ariz.
82. Iwata Y, Kotani Y, Hoshino R, et al. Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder [letter]. J Clin Psychiatry. 2000;61:528-529.
83. McMeekin H. Successful treatment of obsessive-compulsive disorder with oxcarbazepine: a case report. J S C Ued Assoc. 2003;98:316-320.
84. Ramesh TC, Khanna S. Lamnotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder [letter]. Aust N Z J Psychiatry. 2000;34:527-528.
85. Fallon BA, Liebowitz MR, Campeas R, et al. intravenous domipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry. 1998;55:918-924.
86. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder an open trial. J Clin Psychiatry 2002;63:796-801.
87. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry. 1997;154:396-401.
88. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry. 1996;153:1219-1221.
89. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol. 1999;2:193-195.
90. Harvey BH, Brink CB, Seedat S, Stein DJ. Defining the neuromolecular action of myo-inositol: application to obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:21-32.
91. Shapira NA, Keck PE, Goldsmith TD, et al. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 1997;6:170-173.
92. Koran LM, Bullock KD, Franz BE, et al. Double-blind oral morphine in treatment-resistant OCD. Presented at: Annual Meeting of the American Psychiatric Association. May 17-22, 2003; San Francisco, Calif.
93. Tao R, Auerbach SR. Increased extracellular serotonin in rat brain after systemic or intraraphe administration of morphine. J Neurochem. 1994;63:517-524.
94. Spampinato U. Serotonin agonists reduce dopamine synthesis in the striatum only when the impulse flow of nigro-striatal neurons is intact. Brain Res. 1985;328:89-95.
95. Koran LM, Quirk T, Lorberbaum JP, Elliott M. Mirtazapine treatment of obsessive-compulsive disorder [letter]. J Clin Psychopharmacol. 2001;21:537-539.
96. Koran LM, Chuong HW. Mirtazapine treatment for adult OCD. Poster presented at: Annual Meeting of the American Psychiatric Association. May 17-22, 2003; San Francisco, Calif.
97. Maina G, Albert U, and Bogetto F. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2001;16:33-38.
98. Freud S. Two case histores: little Hans and the rat man. In: Strachey J, ed. The Standard Edition of the Compete Psychological Works of Sigmund Freud. Vol 10. London, UK: Hogarth Press; 1953.
99. Keijsers G, Hoogduin C, Shaap C. Predictors of treatment outcome in the behavioural treatment of obsessive-compulsive disorder. Br J Psychiatry. 1994;165:781-786.
100. Marks I. Behavior therapy for obsessive-compulsive disorder: a decade of progress. Can J Psychiatry. 1997;42:1021-27.
101. Foa EB, Kozak MJ. Psychological treatment for obsessive-compulsive disorder. In: Mavissakalian MR, Prien RF, eds. Long-term Treatments of Anxiety Disorders. Washington, DC: American Psychiatric Press; 1996:285-309.
102. Christensen H, Hadzi-Pavlovic D, Andrews G, Mattick R. Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1987;55:701-711.
103. Cox BJ, Swinson RP, Morrison B, Lee PS. Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. J Behav Ther Exp Psychiatry. 1993;24:149-153.
104. van Balkom AJ, van Oppen P, Vetmeulen AW, et al. A meta-analysis on the treatment of obsessive-compulsive disorder: comparison of antidepressants, behavior, and cognitive therapy. Clin Psychol Rev. 1994;5:359-381.
105. Hembree EA, Riggs DS, Kozak MJ, et al. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectr. 2003;8:363-371,381.
106. Albert U, Maina G, Forner F, Bogetto F. Cognitive-behavioral therapy in obsessive-compulsive disorder patients partially unresponsive to SRIs [abstract]. Eur Neuropsychopharmacol. 2003;13(suppl 4):S357-S358.
107. James IA, Blackburn IM. Cognitive therapy with obsessive-compulsive disorder. Br J Psychiatry. 1995;166:444-450.
108. Fals-Stewart W, Marks AP, Schafer J. A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder. J Nerv Ment Dis. 1993;181:189-193.
109. van Noppen BL, Pato MT, Marsland R, Rasmussen SA. A time-limited behavioral group for treatment of obsessive-compulsive disorder. J Psychother Pract Res. 1998;7:272-280.
110. Rauch SL, Jenike MA, Alpert NM, et al. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using 15-O labeled CO2 and positron emission tomography. Arch Gen Psychiatry. 1994;1:62-70.
111. Saxena S, Brody AL, Schwartz JM, Baxter LR. Neuorimaging and frontal-subcortical circuitry in obsessive compulsive disorder. Br J Psychiatry. 1998;173(suppl 35):26-38.
112. Vogt BA, Pandya DN. Cingulate cortex of the rhesus monkey. II: Cortical afferents. J Comp Neurol. 1987;262:271-289.
113. Cavada C, Company T, Tejedor J, et al. The anatomical connections of the macaque monkey orbitofrontal cortex. Cereb Cortex. 2000;10:220-242.
114. Kemp JM, Powell TPS. The cortico-striate projections in the monkey. Brain. 1970;93:525-546.
115. Martuza RL, Chiocca EA, Jenike MA, et al. Stereotactic radiofrequency thermal cingulotomy for obsessive compulsive disorder. J Neuropsychiatry Clin Neurosci. 1990;2:331-336.
116. Cosgrove GR, Rauch SL. Psychosurgery. Neurosurg Clin N Am. 1995;6:167-176.
117. Kelly D, Richardson A, Mitchell-Heggs N. Stereotactic limbic leucotomy: neurophysiological aspects and operative technique. Br J Psychiatry. 1973;123:133-140.
118. Rauch SL, Markris N, Cosgrove GR, et al. A magnetic resonance imaging study of regional cortical volumes following sterotactic anterior cingulotomy. CNS Spectr. 2001;6:214-222.
119. Sachdev P, Trollor J, Walker A, et al. Bilateral orbitomedial leuocotomy for obsessive-compulsive: a single-case study using positron emission tomography. Aust N Z J Psychiatry. 2001;35:684-690.
120. Cosgrove GR, Ballantine HT Jr. Cingulotomy in psychosurgery. In: Goldenberg PL, Tasker RR, eds. Textbook of Sterotactic and Functional Neurosurgery. New York, NY McGraw-Hill; 1998:1965-1970.
121. Dougherty DD, Baer L, Cosgrove GR, et al. Update on cingulotomy for intractable obsessive-compulsive disorder: prospective long-term follow-up of 44 patients. Am J Psychiatry. 2002;159:269-275.
122. Baer L, Rauch SL, Ballantine HT Jr, et al. Cingulotomy for intractable obsessive-compulsive disorder. Prospective long-term follow-up of 18 patients. Arch Gen Psychiatry. 1995;52:384-392.
123. Marin RS. Apathy: Concept, syndrome, neural mechanisms, and treatment. Semin Clin Nearopsychiatry. 1996;1:304-314.
124. Athwal BS, Berkley KJ, Hussain I, et al. Brain responses to changes in bladder volume and urge to void in healthy men. Brain. 2001;124:369-377.
125. Devinsky O, Morrell MJ, Vogt BA. Contributions of the anterior cingulated cortex to behavior. Brain. 1995;118:279-306.
126. Ballantine HT Jr. Neurosurgery for behavioral disorders. In: Wilkins RH, Rengachary SS, eds. Neurosurgery. New York, NY: Elsevier/North Holland Biomedical Press; 1985:2527-2537.
127. Kim CH, Chang JW, Koo MS, et al. Anterior cingulotomy for refractory obsessive-compulsive disorder. Acta Psychiatr Scand. 2003;107:283-290.
128. Spanglet WJ, Cosgrove GR, Ballantine HT, et al. Magnetic resonance image-guided Stereotactic cingulotomy for intractable psychiatric disease. Neurosurgery. 1996;38:1071-1078.
129. Jenike MA, Baer L, Ballantine HT Jr, et al. Cingulotomy for refractory obsessive-compulsive disorder: A long-term follow-up of 33 patients. Arch Gen Psychiatry. 1991;48:548-555.
130. Rauch SL, Dougherty DD, Cosgrove GR, et al. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder. Biol Psychiatry. 2001;50:659-667.
131. Montoya A, Weiss AP, Price BH, et al. Magnetic resonance imaging-guided stereotactic limbic leucotomy for treatment of intractable psychiatric disease. Neurosurgery. 2002;50:1043-1052.
132. Hay P, Sachdev P, Cumming S, et al. Treatment of obsessive-compulsive disorder by psychosurgery. Acta Psychiatr Scand. 1993;87:197-207.
133. Kim MC, Lee TK, Choi CR. Review of long-term results of stereotactic psychosurgery. Neurol Med Chir (Tokyo). 2002;42:365-371.
134. George MS, Post RM, Ketter TA, et al. Neural mechanisms of mood disorders. Curr Rev Mood Anxiety Disord. 1997;1:71-83.
135. Van Bockstaele EJ, Peoples J, Valentino RJ. Anatomic basis for differential regulation of the rostrolateral peri-locus coeruleus region by limbic afferents. Biol Psychiatry. 1999;46:1352-1363.
136. Malhi GS, Sachdev P. Novel physical treatments for the management of neuropsychiatric disorders. J Psychosom Res. 2002;53:709-719.
137. Harden CL, Pulver MC, Ravdin CL, et al. A pilot study of mood in epilepy patients treated with vagus nerve stimulation. Epilepsy Behav. 2002;1:93-99.
138. Jobe PC, Dailey JW, Wernicke JF. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol. 1999;13:317-356.
139. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000;47:276-286.
140. Ward H, Ninan PT, Pollack M, et al. Treatment-refractory obsessive-compulsive disorder: potential benefit of VNS therapy. Poster presented at: Annual Meeting of the Anxiety Disorders Association of America. March 27-30, 2003; Toronto, Canada.
141. George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation: applications in psychiatry. Arch Gen Psychiatry. 1999;56:300-311.
142. Greenberg BD, Rezai AR. Mechanisms and the current state of deep brain stimulation in neuropsychiatry. CNS Spectr. 2003;8:522-526.
143. Nuttin BJ, Gabriels LA, Cosyns PR, et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery. 2003;52:1263-1274.
144. Barker AT, Jalinous R, Freeston IL. Non-invasive stimulation of the human motor cortex. Lancet. 1985;1:1106-1107.
145. Greenberg BD, George MS, Dearing J, et al. Effect of prefrontal repetitive transcranial magnetic stimulation (rTMS) in obsessive-compulsive disorder: a preliminary study. Am J Psychiatry. 1997;154:867-869.
146. Alonso P, Pujol J, Cardoner N, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: A double-blind, placebo-controlled study. Am J Psychiatry. 2001;158:1143-1145.
147. Martin JLR, Barbanoj MJ, Clos S. Transcranial magnetic stimulation (TMS) for the treatment of obsessive-compulsive disorder (OCD). Cochrone Database Syst Rev 2003;3:CD003387.
148. Wasserman EM. Risk and safety of repetitive transcranial magnetic stimulation (report and suggested guidelines from the International Workshop in the Safety of Repetitive Trnascranial Magnetic Stimulation, June 5-7, 1996). Electroencephalogr Clin Neurophysiol. 1998;108:1-16.
149. Wasserman EM, Cohen LG, Flitman SS, et al. Seizures in healthy people with repeated "safe" trains of transcranial magnetic stimuli. Lancet. 1996;47:825-826.
150. Rudorfer MV. Electroconvulsive therapy in treatment-refractory obsessive-compulsive disorder. In: Goodman WK, Rudorfer MV, Maser JD, eds. Obsessive-Compulsive Disorder: Contemporary Issues in Management. London, UK: Lawrence Erlbaum Associates; 2000:431-455.